See ratings and reviews when you sign up for an account.

A Pilot Study to Evaluate the Quality of Life of Long Term Survivors of Adult Acute Lymphoblastic Leukemia

This study is currently Recruiting

September 2011 By University Health Network, Toronto

First Recieved on June 21, 2010

Last Updated on September 22, 2011

Sponsor: University Health Network, Toronto
Information provided by: University Health Network, Toronto
Identifier: NCT01148927


Acute lymphoblastic leukemia (ALL) accounts for about 20% of adult leukemias. Treatment results in adult ALL have lagged behind the improvements achieved in the pediatric population. A modified version of the Dana Farber Cancer Institute pediatric protocol is used to treat adult patients with ALL. The results seem to be superior to those reported with other adult protocols. However, there is limited data on the impact of such intensified approaches and resulting toxicities on the quality of life (QOL) of these survivors. Identifying important factors affecting the QOL may permit attempts at early interventions and may help to further modify the regimen and mitigate these adverse effects on QOL. This study is evaluating the quality of life of long term survivors of adult ALL. It involves the patients filling out several questionnaires that are well-validated measures assessing various QOL issues of concern to these patients. The following questionnaires are used in this study: - EORTC QLQ C30 to assess global health and major health domains - Brief Pain Inventory (BPI) - Personal Health Questionnaire (PHQ9) to assess psychosocial distress - Functional Assessment of Cancer Therapy (FACT) Fatigue Questionnaire - Peripheral Neuropathy Questionnaire The data obtained from the questionnaires will be analyzed and the various domains of health will be quantified.

Study Type: Observational
Study Design: Observational Model: Case-Only, Time Perspective: Prospective


Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: - previously diagnosed with adult ALL or T-lymphoblastic lymphoma - Age >/= 18 - Have completed the two-year modified DFCI protocol at least three months earlier and are in continuous complete remission - Understand English and are able to fill out questionnaires


  • Investigator: Joseph M Brandwein, MD, FRCPC - Principal Investigator - Princess Margaret Hospital, Canada


  • Princess Margaret Hospital

    Toronto, Ontario M5G 2M9 Canada

Conditions related to this trial:

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.